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rather than Leu 81 . Finally, secretion of mutant p.L104P from transfected cells was markedly reduced due to intracellular retention and aggregation with concomitant elevation of ER stress markers. We conclude that PRSS1 variant p.L104P exhibits a variety of phenotypic changes that can increase risk for chronic pancreatitis. Mutationinduced misfolding and associated ER stress are the dominant effects that support a direct pathogenic role in chronic pancreatitis. chronic pancreatitis; hereditary pancreatitis; trypsinogen activation; autoactivation; endoplasmic reticulum stress; misfolding; intracellular aggregation CHRONIC PANCREATITIS IS A relapsing progressive inflammatory disease of the pancreas that often develops on the basis of genetic predisposition (7, 44) . Susceptibility genes identified to date include, in the order of discovery, PRSS1 (serine protease 1, human cationic trypsinogen), CFTR (cystic fibrosis transmembrane conductance regulator), SPINK1 (serine protease inhibitor Kazal type 1, pancreatic secretory trypsin inhibitor), CTRC (chymotrypsinogen C), CPA1 (procarboxypeptidase A1), and CEL (carboxyl ester lipase) (8, 12, 26, 31, 42, 45, 46) . Mutations in PRSS1, such as p.N29I and p.R122H, are strong risk factors that cause autosomal dominant hereditary pancreatitis with incomplete penetrance and variable expressivity (20) . Although less well characterized, CPA1 mutations also confer strong predisposition resulting in early onset disease (45) . In contrast, risk variants of other genes typically confer smaller but significant risk and are often found in the transheterozygous state in affected carriers (25) . More recently, a GWAS study identified common variants in the CLDN2 locus and in the promoter region of PRSS1 that appear to increase disease risk only by a small degree (10, 43) .
Mechanistic studies revealed that mutations in most risk genes result in premature intrapancreatic trypsinogen activation. Thus, high-penetrance PRSS1 variants cause higher trypsin levels either by stimulating trypsinogen autoactivation and/or by inhibiting CTRC-dependent trypsinogen degradation (13, 33) . Loss-of-function mutations in the protective trypsin inhibitor SPINK1 or the trypsinogen-degrading enzyme CTRC can also result in elevated trypsin activity (1, 4, 5, 15, 18, 26) . Consistent with the trypsin paradigm, a rapidly autodegrading variant of PRSS2 encoding human anionic trypsinogen was shown to protect against chronic pancreatitis (47) . Finally, variants that diminish CFTR function can stimulate trypsinogen activation through impaired ductal flushing and/or altered intraluminal pH (24) .
Investigations into the cellular effects of pancreatitis-associated mutations revealed an alternative disease mechanism unrelated to trypsin activity, i.e., mutation-induced protein misfolding and consequent endoplasmic reticulum (ER) stress (1, 14, 30, 39, 45) . CPA1 mutations and some PRSS1 variants are most likely to exert their pathogenic effect via this pathway (14, 30) although misfolding was also observed with a handful of CTRC (1, 39) and SPINK1 (4, 5, 18) variants, and it may also underlie the mechanism of action of the recently described CEL hybrid variant (12) . The PRSS1 variants that appeared to cause misfolding (p.K92N, p.D100H, p.R116C, p.S124F, p.C139F, p.C139S, p.G208A) were typically rare and found in sporadic idiopathic cases (14, 30 , and references therein).
The c.311TϾC (p.L104P) human cationic trypsinogen variant was first reported in three heterozygous carriers of a German pedigree with a history of abdominal pain and diabetes but without clinically proven chronic pancreatitis (40) . The same variant was later identified in a subject of Chinese origin with idiopathic chronic pancreatitis (6) . The limited clinical and genetic data do not allow conclusive determination whether or not the p.L104P variant is pathogenic. The Leu 104 residue forms part of the conserved hydrophobic S2 subsite (Schechter-Berger nomenclature) (29) of the substrate binding site of trypsin. Natural PRSS1 variants affecting the substrate binding site of trypsin have not been described before, and in this regard variant p.L104P is unique. Therefore, in the present study, we set out to investigate the biochemical and cellular effects of variant p.L104P to confirm or rule out a possible pathogenic role in chronic pancreatitis.
MATERIALS AND METHODS
Materials. Expression and purification of recombinant CTRC, CTRB1, CTRB2, CPA1, SPINK1, and ecotin have been described previously (18, 19, 23, 33, 34, 37, 38, 45) .
Nomenclature. Amino acid residues in human cationic trypsinogen were numbered starting with the initiator methionine of the primary translation product according to the recommendations of the Human Genome Variation Society. The reference sequence used was NM_002769. 4 .
Plasmid construction and mutagenesis. The pTrapT7 PRSS1, pTrapT7 intein-PRSS1, and pcDNA3.1(Ϫ) PRSS1 expression plasmids were constructed previously (17, 22, 27, 28) . Missense mutation p.L104P was generated by overlap extension PCR mutagenesis and cloned into the expression plasmids.
Expression and purification of recombinant trypsinogen. Wild-type and p.L104P cationic trypsinogens were expressed in Escherichia coli BL21(DE3) as cytoplasmic inclusion bodies (27, 28) . For autoactivation experiments in the presence of CTRC, trypsinogens were expressed as fusions with a self-splicing mini-intein in the aminopeptidase P-deficient LG-3 E. coli strain (16, 17) . After self-splicing, this construct generates homogeneous intact NH 2-termini not processed by cellular aminopeptidases. Refolding and purification of trypsinogen on immobilized ecotin was carried out as reported previously (16) . Concentrations of purified trypsinogen preparations were determined from the ultraviolet absorbance at 280 nm using the extinction coefficient 37,525 M Ϫ1 ·cm Ϫ1 SPINK1 binding assays. Binding of wild-type and p.L104P mutant human cationic trypsin to the trypsin inhibitor SPINK1 was characterized by measuring the K D value of the reaction in equilibrium, as we described previously (32, 35) . Trypsin concentrations were determined by titration against ecotin, and SPINK1 concentration was determined by titration against wild-type human cationic trypsin. Wild-type (50 pM) and mutant (500 pM) trypsin were incubated overnight (for 16 h) with increasing concentrations of the inhibitor ranging from 0 to 100 pM for wild-type trypsin and 0 to 1,000 pM for the mutant trypsin. Residual trypsin activity was measured with 150 M N-CBZ-Gly-Pro-Arg-7-amido-4-methylcoumarin in 0.1 M Tris·HCl (pH 8.0), 1 mM CaCl 2, and 0.05% Tween 20. The increase in fluorescence was monitored at 380 nm excitation and 460 nm emission wavelengths continuously for 10 min at 22°C. The free protease concentration was plotted as a function of the total inhibitor concentration, and the experimental points were fitted with the following equation:
where the independent variable x represents the total inhibitor concentration, the dependent variable y is the free protease concentration in equilibrium, K is K D, and E denotes the total protease concentration.
Trypsinogen autoactivation. Wild-type and mutant trypsinogen at the indicated concentration (1 or 2 M) were incubated in the absence or presence of 5, 10, 25, and 50 nM human CTRC and 10 nM cationic trypsin in 0. Cell culture and transfection. Human embryonic kidney (HEK) 293T cells were cultured in six-well tissue culture plates (10 6 cells/ well) in DMEM supplemented with 10% fetal bovine serum, 4 mM glutamine, and 1% penicillin/streptomycin solution at 37°C in a humidified atmosphere containing 5% CO 2. Transfections were performed using 4 g pcDNA3.1(Ϫ) PRSS1 plasmid and 10 l Lipofectamine 2000 (Invitrogen) in 2 ml DMEM. After overnight incubation at 37°C, cells were rinsed and overlaid with 2 ml OptiMEM medium (Invitrogen). Media and cells were collected 48 h after this medium change.
Measurement of trypsin activity in conditioned media. Aliquots (50 l) of conditioned media were supplemented with 0.1 M Tris·HCl (pH SDS-PAGE and Western blotting. Conditioned media (200 l) were precipitated with 10% trichloroacetic acid (final concentration), resuspended in 20 l Laemmli sample buffer containing 100 mM dithiothreitol, heat-denatured at 95°C for 5 min, and run on 15% SDS-polyacrylamide gels. The gels were stained with Coomassie blue R-250. For Western blotting, conditioned media (5 l) or cell lysates (20 g total protein) were directly mixed with sample buffer and electrophoresed as described above. Proteins were transferred to Immobilon-P membranes (Millipore, Bedford, MA) at 350 mA for 1 h. Trypsinogen was detected with a sheep polyclonal antibody (no. AF3848; R&D Systems) used at a dilution of 1:5,000 followed by horseradish peroxidase (HRP)-conjugated donkey polyclonal antisheep IgG (no. HAF016; R&D Systems) used at 1:2,000 dilution. Incubations with primary and secondary antibodies were performed at room temperature for 1 h each. HRP was detected using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific).
Reverse transcription-PCR analysis. RNA was isolated from HEK 293T cells transfected with given plasmids using the RNeasy Mini Kit (Qiagen), and 2 g RNA were reverse-transcribed with the HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems). Semiquantitative measurements of X-box-binding protein 1 (XBP1) mRNA splicing were performed by PCR using primers that amplify both the spliced and unspliced forms and generate 441-and 415-bp amplicons, respectively. XBP1 primers were as follows: sense primer, 5=-CCT TGT AGT TGA GAA CCA GG-3= and antisense primer, 5=-GGG CTT GGT ATA TAT GTG G-3=. The PCR amplicons were separated by agarose gel electrophoresis, stained with ethidium bromide, and photographed. The fraction of spliced XPB1 was then determined by densitometry. Levels of immunoglobulin-binding protein (BiP) mRNA were determined using quantitative PCR with TaqMan primers and TaqMan Universal PCR Mastermix (Applied Biosystems). Gene expression was quantitated using the comparative C T method (⌬⌬CT method). Expression levels of BiP were first normalized to those of the glyceraldehyde-3-phosphate dehydrogenase internal control gene (⌬C T) and then to expression levels measured in cells transfected with empty vector (⌬⌬CT). Results were expressed as fold changes calculated with the formula 2 Ϫ⌬⌬CT .
RESULTS
Modeling the effect of the p.L104P mutation. Position 104 in human cationic trypsinogen corresponds to amino acid 99 in the conventional numbering of chymotrypsin-like serine proteases, and it usually harbors aliphatic amino acids such as the Leu found in human trypsins. This residue helps to shape the S2 subsite, which is also lined by His 63 (chymotrypsin numbering His 57 ) and Trp 216 (chymotrypsin numbering Trp 215 ). Although the S2 site is relatively hydrophobic, with the exception of Asp and Glu, it can accommodate a variety of residues with little selectivity (3, 11) . The side chain of Leu 104 can form van der Waals contacts with the P2 side chain of the bound substrate or inhibitor, as seen, for example, in the structure of the Michaelis complex of an inactive bovine trypsin mutant with the Pittsburgh variant of the ␣ 1 -antitrypsin inhibitor ( Fig.  1) Catalytic activity of p.L104P cationic trypsin. Determination of the kinetic parameters of the mutant enzyme on small synthetic substrates N-CBZ-Gly-Pro-Arg-p-nitroanilide and N-CBZ-Gly-Pro-Arg-7-amido-4-methylcoumarin revealed an ϳ10-fold decrease in the catalytic efficiency that was mostly attributable to an increase in the K M (Table 1) . Larger protein substrates were also cleaved less efficiently by the mutant. Thus, the mutant enzyme activated human chymotrypsinogens B1, B2 (data not shown), and C ϳ20-fold slower relative to wild-type cationic trypsin, whereas activation of human proCPA1 was reduced by about twofold (Fig. 2) . Finally, mutant p.L104P digested bovine ␤-casein at a twofold decreased rate (Fig. 3) .
Autoactivation of p.L104P cationic trypsinogen. Experiments described above indicate that the p.L104P trypsin mutant cleaves a variety of substrates at a reduced rate. Remarkably, however, this was not the case when trypsinmediated trypsinogen activation (autoactivation) was tested. When measured at pH 8.0 in 1 mM calcium, the mutant trypsinogen autoactivated slightly faster than wild type (Fig.  4A) . SDS-PAGE analysis of the autoactivation process confirmed more rapid conversion of the p.L04P trypsinogen band to trypsin compared with wild-type cationic trypsinogen (Fig. 4B) . Interestingly, the typically seen proteolytic fragments resulting from cleavage of the Arg 122 -Val 123 peptide bond were much less noticeable in case of the mutant enzyme, indicating that this autolytic site is poorly cleaved by p.L104P trypsin (Fig. 4B) . Autoactivation of human cationic trypsinogen is regulated by CTRC through specific proteolytic cleavages. When autoactivation of wild-type trypsinogen is measured in the presence of CTRC, the rate is slightly increased due to processing of the activation peptide to a shorter form, whereas trypsin levels are markedly reduced due to trypsinogen degradation (33) . This latter process requires not only a CTRC-mediated cleavage after Leu 81 in the calcium-binding loop but also an autolytic cleavage after Arg 122 . Compared with wild-type cationic trypsinogen, autoactivation of mutant p.L104P was less affected by CTRC, and the mutant autoactivated to higher trypsin levels (Fig. 5) , e.g., in the presence of 50 nM CTRC, mutant activity reached ϳ35%, whereas wild type plateaued at 15% of potential maximal activity. Visualizing the activation reaction on Coomassie blue-stained gels confirmed the stronger trypsin bands in the p.L104P mutant and the absence of the proteolytic fragments due to cleavage at Arg 122 (Fig. 5C) . Thus, the apparent resistance of p.L104P trypsinogen to CTRC-mediated degradation is due to the defective autolytic cleavage of the (Fig. 6) .
Binding of SPINK1 trypsin inhibitor to p.L104P trypsin. The physiological inhibitor SPINK1 binds with high affinity to cationic trypsin. In equilibrium-binding assays, we determined a K D value of 3.9 Ϯ 0.4 (SE) pM (n ϭ 3). In contrast, SPINK1 bound to mutant p.L104P with a K D of 284 Ϯ 56 (SE) pM (n ϭ 3), indicating a 70-fold decreased affinity as a result of less favorable S2-P2 interactions (Fig. 7) . As a control experiment, we also measured inhibition by the small-molecule trypsin inhibitor benzamidine, which binds to the primary specificity pocket of trypsin and does not make extended subsite contacts. Wild-type and p.L104P mutant trypsin were inhibited by benzamidine with K i values of 32 and 42 M, respectively, indicating that mutation p.L104P has no significant effect on the primary binding pocket of trypsin (reviewed but not shown).
Secretion of p.L104P trypsinogen. To study the effect of the p.L104P mutation on cellular secretion of trypsinogen, we transiently transfected HEK 293T cells with expression plasmids carrying wild-type and mutant cationic trypsinogen cDNA. Although 293T cells do not have a regulated secretory pathway as acinar cells, this cell line has been exceedingly useful to characterize mutation-induced misfolding and secretion defects, since these cells do not secrete endogenous proteins to a significant level and, unlike acinar cells, can be transfected using expression plasmids with high efficiency (14, 30) . Secretion of cationic trypsinogen in the incubation medium was measured by SDS-PAGE, Western blot, and activity assays (Fig. 8) . Remarkably, all three approaches indicated that . At the indicated times, 2-l aliquots were removed, and trypsin activity was measured as described in MATERIALS AND METHODS. Trypsin activity was expressed as percentage of the maximal activity measured in the absence of CTRC. C: autoactivation in the presence of 10 nM CTRC was also followed by SDS-PAGE. At the indicated times, 150-l aliquots were precipitated with 10% trichloroacetic acid, electrophoresed on 15% SDS-PAGE gels, and stained with Coomassie blue. The faint proteolytic fragment observed in the wild-type sample at 15 kDa corresponds to the COOH-terminal chain of trypsin cleaved at the Arg 122 autolytic site. Representative graph and gel from two experiments are shown. secretion of the p.L104P mutant was markedly reduced. As judged by the trypsin activity measured in the medium after enteropeptidase activation, the extent of the secretion defect was about ninefold relative to wild type (Fig. 8C) .
To address the cause of the secretion defect, we used Western blot to detect trypsinogen in cell lysates. The amount of intracellular trypsinogen was comparable in cells transfected with wild-type and p.L104P trypsinogen constructs, indicating that the mutant enzyme is translated normally but becomes intracellularly retained, most likely due to misfolding in the ER (Fig. 9A) . To determine whether aggregation could play a role in intracellular retention, we separated the insoluble trypsinogen fraction by ultracentrifugation of cell lysates. Insoluble trypsinogen was recovered only in the pellet of lysates from cells expressing p.L104P mutant but not from cells expressing wild-type trypsinogen, demonstrating that the mutant enzyme is more prone to aggregation intracellularly (Fig. 9B) .
ER stress in HEK 293T cells expressing p.L104P trypsinogen. The apparent secretion defect and intracellular aggregation of mutant p.L104P suggest the possibility of misfolding-induced ER stress, as we observed previously with other mutant digestive enzymes (1, 30, 36, 39, 45) . To test for ER stress, we examined mRNA levels of the ER chaperon BiP and analyzed the inositol-requiring enzyme 1 (IRE1)-mediated mRNA splicing of the transcription factor XBP1. Both ER stress markers were significantly elevated in cells expressing p.L104P trypsinogen (Fig. 10) .
DISCUSSION
In the present study we investigated the functional effects of the p.L104P PRSS1 variant to determine whether this rare variant might play a pathogenic role in chronic pancreatitis. We focused our attention on this mutation because this is the only natural PRSS1 variant that affects the substrate binding site of trypsin. Specifically, the mutation alters the S2 subsite, Fig. 8 . Effect of mutation p.L104P on cellular secretion of trypsinogen. HEK 293T cells were transiently transfected with expression plasmids for wild-type and mutant human cationic trypsinogen, and conditioned media were collected after 48 h. Trypsinogen protein levels were determined by Coomassie bluestained SDS-polyacrylamide gels (A), by Western blots (B), and by measuring trypsin activity in the medium after activation with enteropeptidase (C). Trypsinogen protein levels secreted in the media were calculated from the enzyme activity (mean Ϯ SD, n ϭ 8, ****P Ͻ 0.0001). Representative gel and blot from three experiments are shown. a hydrophobic groove that imparts broad P2 specificity to trypsin (9, 11) . In addition, the main chain N of position 104 forms an H bond with position 100 that stabilizes the loop between amino acids 97 and 107. Because Pro cannot act as an H donor, the p.L104P mutation may destabilize the Pro 97 -Asp 107 loop and change the S2 site more profoundly and in a somewhat unpredictable manner. Consistent with our predictions of altered subsite specificity, we found that p.L104P trypsin cleaved peptide and protein substrates with reduced efficiency and bound the physiological trypsin inhibitor SPINK1 with decreased affinity. There was no clear relationship between the magnitude of the reduction in activity/binding and the physicochemical properties of the P2 side chains, e.g., both CTRB1 and proCPA1 contain a Ser residue in the P2 position with respect to the activating peptide bond, yet trypsin-mediated activation of CTRB1 was more severely impacted by the p.L104P mutation (20-fold decrease) than activation of proCPA1 (2-fold decrease). On the other hand, the p.L104P mutant exhibited slightly increased autoactivation, indicating that cleavage of the trypsinogen activation peptide by p.L104P trypsin was somewhat improved. The P2 position in the trypsinogen activation peptide corresponds to Asp 22 . Acidic residues, Asp in particular, are not tolerated well in the otherwise broadly specific S2 subsite of trypsin (21) . Accordingly, Asp 22 serves as a critical inhibitor of trypsinogen autoactivation, and mutation of Asp 22 to Gly (p.D22G) or Ala (p.D22A) results in markedly accelerated autoactivation (13, 21) . In case of the p.L104P mutant, the altered S2 subsite seems to accommodate the P2 Asp 22 slightly better, resulting in the small increase in autoactivation.
Surprisingly, autoactivation of the p.L104P mutant was not suppressed well by CTRC-mediated degradation, and the mutant autoactivated to higher trypsin levels than wild-type pancreas. Although active p.L104P trypsin may not be as harmful because of its defective cleavage of most protein substrates, it can still promote autoactivation of wild-type cationic trypsinogen produced from the wild-type allele in heterozygous carriers. Thus, the biochemical basis for a potentially strong pathogenic effect of the p.L104P mutation has been identified. The caveat to this conclusion is that mutant p.L104P needs to be produced and secreted to normal levels, which turned out not to be the case.
Unexpectedly, we found that the p.L104P mutation caused intracellular retention and aggregation of trypsinogen in transfected 293T cells. Consistent with an interpretation of mutation-induced misfolding, we observed elevated ER stress markers in cells expressing the p.L104P mutant. Thus, the dominant effect of mutation p.L104P appears to be not biochemical but cell biological. In other words, the mutation belongs to the class of variants that act through the misfolding-dependent pathway rather than the trypsin-dependent pathway. Although the exact mechanism by which mutation p.L104P causes misfolding is not readily apparent, the loss of a potentially important H bond that stabilizes the Pro 97 -Asp 107 loop is likely a contributing factor.
Mutation-induced misfolding and consequent perturbations of ER homeostasis have been conclusively linked with chronic pancreatitis. First, mutations p.R116C and p.C139S in PRSS1 were found to undergo misfolding with consequent ER stress, suggesting that some trypsinogen variants might exert their effects via a mechanism that is unrelated to trypsin activity (14) . This conclusion was later supported by analysis of 13 rare PRSS1 variants presumed to cause pancreatitis (30) . Among these, five variants exhibited strong (p.D100H, p.C139F) or moderate (p.K92N, p.S124F, p.G208A) secretion defects suggestive of misfolding, although ER stress has not been studied. It is interesting to note that misfolding PRSS1 variants were typically found in cases of sporadic chronic pancreatitis with no family history, suggesting a milder pathogenic effect relative to the trypsin-dependent high-penetrance mutations such as p.R122H. Additional evidence for the role of misfolding in chronic pancreatitis came from studies on the CPA1 gene that demonstrated that loss-of-function CPA1 variants are associated with early onset disease and represent strong risk factors (45) . The majority of CPA1 variants found in patients exhibited severely reduced cellular secretion due to intracellular retention and degradation. With the use of the relatively more frequent p.N256K variant as a test case, strong ER stress was demonstrated in AR42J acinar cells expressing mutant CPA1 (45) . Besides PRSS1 and CPA1 mutations, some CTRC variants were also shown to result in misfolding and ER stress (1, 39) . However, in contrast to trypsinogen and procarboxypeptidase that are produced in high abundance by the pancreas, the lower expression levels of CTRC make it questionable whether this mechanism is relevant to the pathogenic action of CTRC variants. Similarly, misfolding SPINK1 variants are unlikely to elicit ER stress due to low expression levels (4, 5, 18) . More recently, association of chronic pancreatitis with a novel duplicated hybrid allele of the CEL gene encoding carboxyl ester lipase was described (12) . Although not demonstrated experimentally, it appears likely that this newly formed lipase molecule could also result in misfolding and ER stress. Finally, a rare pancreatic triglyceride lipase (PNLIP) variant was found in the homozygous state in two brothers with lipase deficiency (2) . Functional analysis revealed that the p.T221M variant caused intracellular retention, loss of secretion, and strong ER stress (36) . Although a diagnosis of chronic pancreatitis has not been established in the published carriers, signs of pancreatic insufficiency have been documented, suggesting that ER stress-related pathology may have contributed to their disease.
The mechanism by which ER stress increases risk for chronic pancreatitis is not completely understood. Chronic unresolved ER stress promotes apoptosis through upregulation of the proapoptotic transcription factor CHOP, and this pathway may contribute to parenchymal atrophy and subsequent fibrosis (41, 48) . Proinflammatory effects of ER stress have been also documented. Thus, translational attenuation by PERK-dependent eIF2␣ phosphorylation results in a relative increase of NF-B vs. its inhibitor IB. Alternatively, NF-B can be activated through degradation of IB as a result of the recruitment and activation of IB kinase by the complex of IRE1 and NF receptor-associated factor 2 (TRAF2). The IRE1-TRAF2 complex can also activate the c-Jun NH 2 -terminal kinase pathway leading to activator protein-1-mediated transcriptional activation of proinflammatory genes (41, 48) . Whether or not these pathways are relevant to the development of chronic pancreatitis remains to be determined.
In conclusion, the observations presented here argue that the p.L104P variant of human cationic trypsinogen increases risk for chronic pancreatitis primarily through misfolding and ER stress. Although biochemical changes also indicate a strong propensity for increased trypsinogen activation, the secretion defect secondary to misfolding would diminish a trypsindependent pathogenic effect.
